Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease

Coronary Artery Disease Clinical Trial

— KARE  

Official title:

Clinical Evaluation of Kaname Cobalt-Chromium Coronary Stent System in the Treatment of Patients With Coronary Artery Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01004575
• Other study ID #: T111E4
• Status: Completed
• Phase: N/A
• Start date: October 2009
• Est. completion date: June 30, 2016

Study information

• Verified date: October 2019
• Source: Terumo Europe N.V.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess whether the new Kaname coronary stent is safe and effective for the treatment of patients with coronary artery disease.

Description:

Current treatments for coronary artery disease include conservative treatment (drug therapies) and invasive techniques that help increase blood flow to ischemic or oxygen-deprived regions of the heart. Among the invasive techniques the most frequently used are coronary artery bypass graft surgery (CABG), and percutaneous transluminal coronary angioplasty (PTCA) without or with stents (bare metal stents (BMS) or drug eluting stents (DES)) implantation. However, all of those treatments have limitations and their effectiveness is diminished under certain circumstances. Therefore, it is essential to tailor therapy for each individual patient considering the overall patient's condition, disease severity and progression as well as concomitant diseases. The question of selection of appropriate stent for each individual patient is still unresolved and most of the physicians either follow international or national guidelines or scientific wisdom.

Although the efficacy of DES is undisputable in restenosis prevention, because some patients could have adverse outcomes from a DES, they should be used selectively in those who are most likely to benefit, and in that decision process several important issues should be addressed such as:Patients' adherence to post-stenting therapy, Bleeding risk, Need for elective surgery, Risk for restenosis, Risk for stent thrombosis. It is still believed that many patients will do well with BMSs and that this technology requires further refinements to improve outcome. For the above reasons Terumo has designed the new coronary BMS, Kaname™, a balloon expandable Cobalt-Chromium (CoCr) stent pre-mounted onto a high pressure, semi-compliant balloon on a rapid exchange delivery catheter. The Kaname stent is the subject of the current prospective, multi-centre KARE study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 282
• Est. completion date: June 30, 2016
• Est. primary completion date: July 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient is = 18 years old.

• Patient is eligible for PCI and acceptable candidate for CABG.

• Clinical evidence of ischemic heart disease and/or a positive functional study. Documented stable angina pectoris (CCS 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia.

• The target lesion or target vessel meets all the following criteria;a) is a single de novo lesion or restenotic post-PTCA (non-stented) lesion in one native coronary artery.b)The stenosis of target lesion is = 50% and < 100% c)The target lesion length must be = 25 mm d)The target reference vessel diameter must be suitable for treatment with stents between 2.5 and 4.0 mm long

• Patient has been informed of the nature of the study, understands the study requirements and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site.

• The patient is able to comply with all specified follow-up evaluations.

Exclusion Criteria:

• Most recent LVEF of the patient is < 25%.

• Known allergies to the following: aspirin, Clopidogrel bisulfate, Prasugrel or Ticlopidine, heparin, cobalt, chromium, nickel, or contrast agent (that cannot be adequately premedicated).

• A platelet count <100,000 cells/mm3 or >700,000 cells/mm3.

• WBC count < 3500 cells/mm3.

• Evidence of MI with positive Troponin within 72 hours of the intended treatment.

• Previous PCI (<30 days) anywhere within the target vessel.

• Planned interventional treatment of any non-target vessel <30 days post-procedure will be required. Planned intervention on the target vessel or on a significant lesion of > 50% stenosis anywhere within the target vessel after the index procedure will be required.

• The target lesion requires treatment with a device other than PTCA balloon prior to stent placement. (e.g. but not limited to directional coronary atherectomy, excimer laser, rotational atherectomy, etc.).

• Previous stenting anywhere within the target vessel.

• Target vessel has evidence of thrombus.

• Excessive tortuousity (> 60°) of the target vessel proximal to the target lesion (visual estimate).

• Either of the following characteristics in the target lesion (visual estimate):

a)Ostial target lesion or bifurcation lesion b)Target lesion involves a side branch > 2mm in diameter c) Target lesion has excessive tortuousity (> 45°)d)Moderate to severely calcified lesion which can not be successfully predilated e)Target lesion is located in or supplied by an arterial or venous bypass graft f)Significant (> 40%) stenosis proximal or distal to the target lesion. g) A complete occlusion (TIMI flow 0 or 1).

• Target lesion located in left main trunk.

• Stroke or transient ischemic attack < prior 180 days.

• Active peptic ulcer or upper GI bleeding < prior 180 days.

• The patient has bleeding hemorrhagic diathesis or coagulopathy. The patient will refuse a blood transfusion.

• The patient has a widespread peripheral vascular disease.

• Acute or chronic renal dysfunction (creatinine > 2.0 mg/dl).

• The patient requires multiple stent implantations for a tandem lesion.

• Life expectancy < 1 year.

• Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. Note: Trials requiring extended follow-up for products that were investigational, but have become commercially available since then, are not considered investigational trials.

• In the investigators opinion patient has a co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study.

• Patient is in cardiogenic shock.

• Female of child-bearing potential.

Related Conditions & MeSH terms

• Angioplasty, Transluminal, Percutaneous Coronary
• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• implantation of Kaname Cobalt-Chromium coronary stent
implantation of Kaname Cobalt-Chromium coronary stent

Locations

Country	Name	City	State
France	Hopital Cardiovasculaire et Pneumologie Louis Pradel	Lyon
France	CHU NORD	Nantes
France	Clinique les Franciscaines	Nimes
France	Hopital d'Instructions des Armées du Val de Grace	Paris CEDEX 05
France	CHU Rangeuil	Toulouse CEDEX 9
Germany	Klinikum Fulda gAG	Fulda
Germany	Klinikum Ludwigshafen	Ludwigshafen
Germany	Klinikum des Johannes Gutenberg Universität	Mainz
Italy	Ospedale Careggi	Florence
Italy	Policlinico Milano	Milan
Italy	Ospedale Civico Palermo	Palermo
Serbia	Clinical Centre of serbia	Belgrade
Serbia	Clinical Hospital Center Zemun	Belgrade
Serbia	Institute for Cardiovascular Disease Dedinje	Belgrade
Spain	Hospital Clinico San Carlos	Madrid
Spain	Hospital La Paz	Madrid
Spain	Hospital Meixoeiro	Vigo

Sponsors (1)

Lead Sponsor	Collaborator
Terumo Europe N.V.

Countries where clinical trial is conducted

France,  Germany,  Italy,  Serbia,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Freedom from Target vessel failure TVF	Freedom from Target vessel failure TVF defined as composite of clinically driven target vessel revascularization (TVR)myocardial infarction or cardiac death that could not be clearly attributed to a vessel other than the target vessel.	6 months post-procedure
Secondary	Freedom from TVF for patients treated with = 3 mm stents.	Freedom from Target Vessel Failure (composite of clinically driven TVR, myocardial infarction or cardiac death that could not be clearly attributed to a vessel other than the target vessel) for patients treated with = 3 mm stents.	6 months post-procedure
Secondary	Freedom from TVF for patients treated with 2.5 and 2.75 mm stents	Freedom from Target Vessel Failure (composite of clinically driven TVR, myocardial infarction or cardiac death that could not be clearly attributed to a vessel other than the target vessel) for patients treated with 2.5 and 2.75 mm stents	6 months post-procedure
Secondary	Freedom from TVF	Freedom from Target Vessel Failure (composite of clinically driven TVR, myocardial infarction or cardiac death that could not be clearly attributed to a vessel other than the target vessel)	30 days,12 months and 3 and 5 years post-procedure
Secondary	Clinically driven target lesion revascularization (TLR) free rate .	Clinically driven target lesion revascularization (TLR) free rate	30 days, 6 and 12 months, 3 and 5 years post-procedure
Secondary	Clinically driven target vessel revascularization (TVR) free rate.	Clinically driven target vessel revascularization (TVR) free rate.	30 days, 6 and 12 months, 3 and 5 years post-procedure
Secondary	Device success	Device success defined as achievement of a residual diameter stenosis of < 50% by QCA or < 30% by visual estimate, using the assigned device only.	Baseline procedure
Secondary	Lesion success	Lesion success defined as the attainment of residual diameter stenosis of < 50% by QCA or < 30% by visual estimate, using any percutaneous method.	Baseline procedure
Secondary	Procedure success	Procedure success defined as achievement of a final diameter stenosis of < 50% by QCA or < 30% by visual estimate, using any percutaneous method, without MACE (composite of cardiac death, MI and TLR) .	During baseline hospital stay
Secondary	Angiographic in-stent acute gain	Angiographic in-stent acute gain at the end of the procedure	Baseline procedure
Secondary	Angiographic in-stent and in-segment binary restenosis rate (= 50%) diameter stenosis	Angiographic in-stent and in-segment binary restenosis rate (= 50%) diameter stenosis	6 months post-procedure
Secondary	Angiographic in-stent, in-segment, proximal, and distal minimum lumen diameter (MLD)	Angiographic in-stent, in-segment, proximal, and distal minimum lumen diameter (MLD)	6 months post-procedure
Secondary	In-stent late-loss	In-stent late-loss (as measured by QCA) defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up MLD.	6 months post-procedure
Secondary	% Diameter Stenosis, in-stent and in-segment .	% Diameter Stenosis, in-stent and in-segment.	6 months post-procedure
Secondary	Neointimal hyperplasia volume as measured by intravascular ultrasound.	Neointimal hyperplasia volume as measured by intravascular ultrasound at 6 months post-procedure	6 months post-procedure
Secondary	Major adverse cardiac events (MACEs) rate .	Major adverse cardiac events (MACEs: composite of cardiac death,, myocardial infarction and TLR) rate.	30 days, 6 and 12 months, 3 and 5 years post-procedure
Secondary	Serious adverse event rate .	Serious adverse event rate.	30 days, 6 and 12 months, 3 and 5 years post-procedure
Secondary	Device failure .	Any device failure	Baseline procedure